Sihuan Pharmaceutical Announces Share Repurchase Amid Strong Financial Results and Strategic Growth
Key Highlights
- Share Repurchase: Sihuan Pharmaceutical Holdings Group Ltd. has executed a share repurchase of 10,000,000 shares at an average price of HK\$1.0685 per share, with a total consideration of approximately HK\$10.685 million.
- Mandate and Timing: The repurchase was conducted under the general mandate granted at the annual general meeting on 6 June 2025. The transaction occurred on 18 May 2026.
- Shareholding Impact: The repurchased shares represent about 0.1095% of the Company’s total issued shares (excluding treasury shares) and are intended to be held as treasury shares for potential future sale or transfer.
- Strong Financial Performance: Sihuan Pharmaceutical posted a revenue of RMB2,618.0 million for 2025, a significant year-on-year increase of 37.7%, and achieved a profit of RMB185.4 million, successfully turning around previous losses.
- Growth in Medical Aesthetics: The medical aesthetics segment has become the largest revenue driver, generating RMB1,485.3 million (up 99.6% YoY), accounting for 57% of total revenue and surpassing the 50% threshold for the first time.
- Strategic International Expansion: The Company has entered the European medical aesthetics market through a strategic investment in Swiss company Suisselle, leveraging an “overseas investment + resource integration” model.
- Innovative Drug Commercialization: The innovative drug business more than doubled its revenue year-on-year and is experiencing rapid commercialization, including new product launches and National Reimbursement Drug List (NRDL) inclusion.
- Shareholder Value Focus: The Board believes the share repurchase will optimize the capital structure, enhance earnings per share, and supports the Company’s strategic trajectory for sustained high growth and shareholder value enhancement.
Details of the Share Repurchase
On 18 May 2026, Sihuan Pharmaceutical repurchased 10,000,000 shares in the open market at an average price of HK\$1.0685 per share, totaling approximately HK\$10.685 million (excluding commissions and other costs). These shares will be held as treasury shares and may be used for future sale or transfer, providing flexibility in capital management and potential support for future corporate actions.
Financial Performance and Strategic Progress
The Company delivered robust financial results in 2025, with revenues rising 37.7% to RMB2,618.0 million. Importantly, Sihuan turned profitable with a net profit of RMB185.4 million, marking a significant turnaround and signaling increased certainty and value realization in its operations.
The medical aesthetics segment is now the Company’s largest pillar, with its revenue surging by 99.6% year-on-year to RMB1,485.3 million. This segment now accounts for 57% of total revenue, crossing the 50% mark for the first time. The growth was fueled by blockbuster products and new drivers, including self-developed flagship regenerative medical aesthetics products that have received multiple marketing approvals and are undergoing rapid commercialization.
Internationally, the Group’s investment in Swiss-based Suisselle has allowed entry into the European market, leveraging an “overseas investment + resource integration” strategy to accelerate global expansion.
The innovative drug business is also experiencing a commercialization harvest period, reporting a more than 100% year-on-year increase in revenue. This has been driven by ongoing breakthroughs in R&D, new product launches, and inclusion in the National Reimbursement Drug List, further supporting sustained growth.
Implications for Shareholders
- The share repurchase demonstrates confidence in the Company’s ongoing growth and commitment to delivering shareholder returns.
- Optimizing capital structure and enhancing earnings per share could have a positive impact on share value.
- The strong financial turnaround, rapid revenue growth, and successful expansion into international markets are all potentially price-sensitive developments that may affect investor sentiment.
- Shareholders should note that the timing, amount, and price of future share repurchases remain at the Board’s discretion and are subject to market conditions.
Company Overview
Founded in 2001 and listed on the Main Board of the Hong Kong Stock Exchange in 2010, Sihuan Pharmaceutical has evolved into an international medical aesthetics and biopharmaceutical company. The Company boasts an independent, leading R&D platform, a diverse global product pipeline, strong product registration capabilities, and a mature, efficient sales system. Sihuan adheres to a “two-wheel drive” strategy, promoting both medical aesthetics and biopharmaceutical businesses, with the aim of becoming a leading player in China’s healthcare sector.
Important Notice
The share repurchase is subject to prevailing market conditions and is at the sole discretion of the Board. There is no guarantee regarding the timing, amount, or price of further repurchases. Shareholders and potential investors are advised to exercise caution when dealing in the Company’s securities.
Disclaimer
The information provided in this article is for informational purposes only and does not constitute investment advice. Investors should make their own assessment and consult professional advisers before making any investment decisions.
四環醫藥公佈股份回購及強勁業績，戰略發展提速
重點摘要
- 股份回購：四環醫藥控股集團有限公司於2026年5月18日回購1,000萬股股份，平均價格每股1.0685港元，總金額約1,068.5萬港元。
- 授權與時機：本次回購根據2025年6月6日股東大會授予的一般授權進行。
- 股份結構影響：回購股份佔公司已發行股份（不包括庫藏股份）約0.1095%，公司擬將該等股份作為庫藏股份保存，未來可再出售或轉讓。
- 財務表現強勁：2025年收入達人民幣26.18億元，同比增長37.7%；溢利1.854億元，成功扭虧為盈，確立盈利增長拐點。
- 醫美業務成最大支柱：醫美板塊收入14.853億元，同比增長99.6%，佔總收入57%，首次超過一半，成為增長主力。
- 國際化擴張：通過投資瑞士Suisselle公司，正式進軍歐洲醫美市場，採用“海外投資+資源整合”模式加速全球化。
- 創新藥商業化突破：創新藥業務收入同比翻倍，進入全面收割期，多個新產品獲批上市及納入國家醫保目錄（NRDL）。
- 對股東的重視：董事會認為股份回購有助優化資本結構、提升每股盈利，契合公司進入高增長階段，將持續提升股東價值。
股份回購詳情
2026年5月18日，公司於公開市場回購1,000萬股股份，平均價格每股1.0685港元，總金額約1,068.5萬港元（不含佣金及其他費用）。這批股份將作為庫藏股份保存，靈活管理資本結構並為未來可能的公司行動提供支持。
財務業績與戰略進展
公司2025年營收同比大幅增長37.7%至26.18億元人民幣，實現淨利潤1.854億元，成功由虧轉盈，為業務帶來更大確定性與價值實現。
醫美業務成為公司最大業務板塊，收入同比增長99.6%至14.853億元，佔總收入57%。該業務由多款自研醫美爆品推動，持續獲批上市並加快商業化進程。
國際化方面，公司通過參股瑞士Suisselle公司，成功進軍歐洲醫美市場，實現海外投資與資源整合，助力全球佈局。
創新藥業務收入同比翻倍，進入全面商業化收割期，多項自主研發產品獲批上市並納入國家醫保目錄，為未來業績持續增長提供強勁動力。
對股東的啟示
- 股份回購顯示公司對未來發展充滿信心，並重視股東回報。
- 資本結構優化及每股盈利提升，有望對股價產生正面影響。
- 業績大幅增長、國際擴張及創新藥商業化突破，均屬重大利好及潛在股價催化劑。
- 惟回購時間、數量及價格由董事會全權決定，受市場情況影響。
公司簡介
四環醫藥集團成立於2001年，2010年於香港主板上市，現已發展為創新驅動的國際醫美及生物醫藥企業，擁有領先的研發平台、豐富的全球產品管線、強大的註冊能力及成熟高效的銷售體系。公司堅持“醫美+生物醫藥雙輪驅動”戰略，致力成為中國領先的行業標杆。
重要提示
股份回購將視乎市場情況，由董事會全權決定，未來回購的時間、數量及價格無任何保證。股東及潛在投資者投資前需審慎行事。
免責聲明
本文資訊僅供參考，並不構成任何投資建議。投資者應自行評估及諮詢專業意見，謹慎作出投資決定。
